Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

This study has been completed.
Information provided by (Responsible Party):
Pamela L. Kunz, Stanford University Identifier:
First received: October 31, 2006
Last updated: October 15, 2013
Last verified: October 2013
Given the lack of other viable treatment options for metastatic neuroendocrine tumors, contrasted with our positive anecdotal experience, and the relative tolerability of the treatment regimen for colorectal cancer patients, we propose a single-institution phase II trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.

Condition Intervention Phase
Neuroendocrine Tumors
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Bevacizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Capecitabine, Oxaliplatin and Bevacizumab for Metastatic or Unresectable Neuroendocrine Tumors

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • 12-month Progression Free Survival (PFS) [ Time Frame: assessed every 3 months by RECIST ] [ Designated as safety issue: No ]
    PFS is defined as the time from enrollment until documented disease progression or death (whichever occurred first).

  • Toxicity by CTCAE Version 3.0 [ Time Frame: Assessed at every visit (approx every 3 wks) ] [ Designated as safety issue: Yes ]
    Participants were monitored every 3 weeks while on study. Toxicity and attributions were as per CTCAE version 3.0 guidelines. Analysis population below is patient who experienced related Grade 3 or higher AE; denominator is 40 total patients enrolled.

Secondary Outcome Measures:
  • Response Rates [ Time Frame: Response rates by RECIST criteria assessed every 3 months ] [ Designated as safety issue: No ]
    Response rate is defined as percent of patients with complete response (CR) and partial response (PR) as their best response as defined by RECIST criteria (version 1).

  • Overall Survival [ Time Frame: Continuous ] [ Designated as safety issue: No ]
    OS is defined as time from enrollment until death from any cause.

  • Biochemical Markers [ Time Frame: Assessed every 3 weeks while on treatment ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: November 2006
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bevacizumab (Avastin), Oxaliplatin (Eloxatin) Drug: Capecitabine
850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
Drug: Oxaliplatin
130 mg/m2 intravenously on day 1 of a 21 day cycle
Drug: Bevacizumab
7.5mg/kg Intravenous on day 1 of a 21 day cycle

Detailed Description:


  1. Determine an estimation of median time to progression (TTP) for patients treated with bevacizumab in combination with capecitabine and oxaliplatin
  2. Assess the toxicities associated with this regimen


  1. Determine objective response rate (RR) for patients treated with this regimen
  2. Conduct exploratory analyses of efficacy according to degree of tumor differentiation and primary location
  3. Determine utility of biochemical markers as a surrogate endpoint for tumor response

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:Subjects must be treated at Stanford University Medical Center for the entire length of study participation.

  • Patients must have histologically or cytologically confirmed neuroendocrine tumor, including both well-differentiated tumors (carcinoid) or moderately to poorly differentiated tumors. Patients must be deemed unresectable due to involvement of critical vasculature, adjacent organ invasion, or presence of metastasis.
  • Patients with prior surgical resection who develop radiological or clinical evidence of metastatic cancer do not require separate histological or cytological confirmation of metastatic disease unless an interval of > 5 years has elapsed between the primary surgery and the development of metastatic disease. Clinicians should consider biopsy of lesions to establish diagnosis of metastatic disease if there is substantial clinical ambiguity regarding the nature or source of apparent metastases.
  • Prior chemotherapy will be permitted, although the patient may not have had prior oxaliplatin.
  • Patients must have a primary or metastatic lesion measurable in at least one dimension by Modified RECIST criteria (see Section 4.2) within 4 weeks prior to entry of study
  • Patients must have ECOG performance status of 0-2
  • Patients must be >= 18 years of age
  • Laboratory values <= 2 weeks prior to randomization:

    • Absolute Neutrophil Count (ANC) >=1500/mm3
    • Platelets (PLT) >= 100,000/mm3
    • Hemoglobin (Hgb) >= 9 g/dL
    • Serum creatinine <= 1.5 x ULN
    • Serum bilirubin <= 1.5 x ULN (<= 3.0 x ULN if liver metastases present)
    • Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT), and alkaline phosphatase <= 3.0 x ULN (<= 5.0 x ULN if liver metastases present). Note: ERCP or percutaneous stenting may be used to normalize the liver function tests.
  • Life expectancy >= 12 weeks
  • Ability to give written informed consent according to local guidelines

Exclusion Criteria:- Disease-Specific Exclusions

  1. Prior oxaliplatin for any reason.
  2. Prior full field radiotherapy <= 4 weeks or limited field radiotherapy <= 2 weeks prior to enrollment. Patients must have recovered from all therapy-related toxicities. The site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease.
  3. Prior biologic or immunotherapy <= 2 weeks prior to registration. Patients must have recovered from all therapy-related toxicities
  4. Prior therapy with anti-VEGF agents
  5. If history of other primary cancer, subject will be eligible only if she or he has:

    • Curatively resected non-melanomatous skin cancer
    • Curatively treated cervical carcinoma in situ
    • Other primary solid tumor curatively treated with no known active disease present and no treatment administered for the last 3 years
  6. Concurrent use of other investigational agents and patients who have received investigational drugs <= 4 weeks prior to enrollment.

    • General Medical Exclusions

1. Subjects known to have chronic or active hepatitis B or C infection 2. History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with study participation or study drug administration or may interfere with the conduct of the study or interpretation of study results 3. Male subject who is not willing to use adequate contraception upon enrollment into this study and for 6 months following the last dose of second-line treatment 4. Female subject (of childbearing potential, post-menopausal for less than 6 months, not surgically sterilized, or not abstinent) who is not willing to use an oral, patch or implanted contraceptive, double-barrier birth control, or an IUD during the course of the study and for 6 months following the last dose of second-line treatment 5. Female subject who is breast-feeding or who has positive serum pregnancy test 72 hours prior to randomization 6. Pleural effusion or ascites that causes respiratory compromise (>= CTCAE grade 2 dyspnea) 7. Any of the following concurrent severe and/or uncontrolled medical conditions within 24 weeks of enrollment which could compromise participation in the study:

  • Unstable angina pectoris
  • Symptomatic congestive heart failure
  • Myocardial infarction <= 6 months prior to registration and/or randomization
  • Serious uncontrolled cardiac arrhythmia
  • Uncontrolled diabetes
  • Active or uncontrolled infection
  • Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
  • Chronic renal disease
  • Acute or chronic liver disease (e.g., hepatitis, cirrhosis) 8. Patients unwilling to or unable to comply with the protocol 9. Life expectancy of less than 12 weeks 10. Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study

    • Bevacizumab-Specific Exclusions

      1. Inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)
      2. Any prior history of hypertensive crisis or hypertensive encephalopathy
      3. New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)
      4. History of myocardial infarction or unstable angina within 6 months prior to study enrollment
      5. History of stroke or transient ischemic attack within 6 months prior to study enrollment
      6. Known CNS disease
      7. Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
      8. Symptomatic peripheral vascular disease
      9. Evidence of bleeding diathesis or coagulopathy
      10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
      11. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
      12. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
      13. Serious, non-healing wound, ulcer, or bone fracture
      14. Urine protein >= 2+ on urinalysis dipstick and >= 1.0 gram on 24-hour urine collection
      15. Known hypersensitivity to any component of bevacizumab
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00398320

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Pamela L. Kunz
Principal Investigator: Pam Kunz Stanford University
  More Information

Responsible Party: Pamela L. Kunz, Assistant Professor of Medicine, Stanford University Identifier: NCT00398320     History of Changes
Other Study ID Numbers: END0002  97273 
Study First Received: October 31, 2006
Results First Received: October 15, 2013
Last Updated: October 15, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Carcinoid Tumor
Neuroendocrine Tumors
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 26, 2016